On August 11, 2022, the Summit Forum on Bone Marrow Inhibition of Shengbai Oral Liquid (Mixture)& Nbsp; Shanxi Station is held in the cloud. The attendees were well-known experts in the field of malignant tumor diagnosis and treatment from Beijing and Shanxi regions. The meeting conducted rich discussions on the ideas of combining traditional Chinese and Western medicine in the diagnosis and treatment of malignant tumors, and the effectiveness of Shengbai oral liquid (mixture) in clinical application. Professor Liu Shuo from Guang'anmen Hospital of the Chinese Academy of Traditional Chinese Medicine reported on the results of preclinical research and post market re evaluation of RCT research, allowing attending experts to deeply understand the effectiveness and safety of the product. Professor Ma Kai from Jincheng People's Hospital highly praised the effectiveness of Shengbai oral liquid (mixture) in clinical application, emphasizing that while Shengbai oral liquid (mixture) increases white blood cells, it also fundamentally improves the hematopoietic function of the bone marrow. Professor Xue Dong from Peking University Cancer Hospital finally summarized the conference, stating that with China's increasing emphasis on the combination of traditional Chinese and Western medicine in the treatment of malignant tumors, traditional Chinese medicine is facing unprecedented opportunities and challenges. In this situation, it is even more important for everyone to jointly discuss new ideas for the combination of traditional Chinese and Western medicine in the diagnosis and treatment of malignant tumors.

本次大会取得圆满成功，梦阳药业也将继续努力，为提升我国中西医结合治疗恶性肿瘤的规范化水平继续做出贡献！

On August 13, 2022, the meeting kicked off with a welcome speech by Professor Sun Tao from Beijing Oriental Hospital, the chairman of the conference. The attending experts come from Beijing Cancer Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing Daxing People's Hospital, and Fangshan First Hospital. At the meeting, numerous experts from traditional Chinese medicine, Western medicine, internal medicine, and surgery jointly discussed the advantages and experience sharing of Shengbai oral liquid. At the same time, based on the experience exchange of typical clinical cases, experts highly recognize the clinical value of Shengbai Oral Liquid, which plays a significant role in reducing toxicity, enhancing efficacy, and immune regulation in the treatment of leukopenia caused by tumor radiotherapy and chemotherapy. The conference came to a successful conclusion through active and enthusiastic discussions. Professor Sun Tao, the chairman of the conference, summarized the situation and gave full recognition to the conference. He hoped to discuss and exchange ideas with numerous experts in traditional Chinese and Western medicine in the future. Mengyang Pharmaceutical will continue to deepen its efforts in the field of cancer treatment, benefiting more patients and continuously improving their quality of life!

The furnace in Jinling continues to heat up. On August 13, 2022, the Clinical Advantages Seminar of Shengbai Oral Liquid was successfully held in Nanjing, Jiangsu. The attending experts came from the General Hospital of the Eastern Theater Command and the Eighty Hospital of the People's Liberation Army. They discussed the mechanism of action, clinical effectiveness, and advantages of Shengbai Oral Liquid in combination with tumor diagnosis and treatment. Experts have shared their insights through evidence-based discussions and typical cases, combined with long-term clinical experience, to further confirm the clear mechanism of action and definite clinical efficacy of using Shengbai Oral Liquid in the treatment of leukopenia after radiotherapy and chemotherapy for malignant tumors. At the same time, during the discussion on the significant therapeutic effect of Shengbai Oral Liquid on patients with concurrent cancer-related fatigue, the attending experts enthusiastically shared, and the atmosphere on site was very lively.

At the end of the meeting, Professor Sun Qian summarized the meeting and expressed expectations for Shengbai Oral Liquid, encouraging our company to continue to work hard and benefit more patients. This conference has achieved a complete success, and Mengyang Pharmaceutical will also bear in mind its mission, aiming to improve the quality of life of cancer patients and bring better treatment to more patients!

On August 23, 2022, the Clinical Application Advantage Practice Forum of Shengbai Oral Liquid (Mixture) - Hebei Station was successfully held in Tangshan City, Hebei Province. The attending experts were from clinical departments such as Oncology, Oncology Surgery, and Radiotherapy at the Affiliated Hospital of North China University of Technology and the People's Hospital of Fengrun District. They jointly discussed the theoretical and practical experience of applying Shengbai Oral Liquid (mixture) in clinical practice, as well as a comprehensive exploration of multiple disciplines in the diagnosis and treatment of malignant tumors. They also discussed the practical experience of the clinical application of Shengbai Oral Liquid (mixture) in surgery, radiotherapy, and chemotherapy. Professor Pang Dequan's lecture on the mechanism and practical application of Shengbai oral liquid (mixture) in the radiotherapy department at the Affiliated Hospital of North China University of Science and Technology brought many surprises to the attending experts, especially in the application and clinical efficacy of radiotherapy throughout the entire process, which was highly recognized. Professor Wang Xiaojing from Fengrun District People's Hospital summarized the conference with unique advantages, interdisciplinary coverage and application, patient-centered approach, comprehensive prevention and treatment of leukopenia, treatment of cancer-related fatigue, and improvement of patient quality of life. This will undoubtedly make Shengbai oral liquid (mixture) shine brightly in clinical application.

结语

The road is long and winding, and I will search up and down. In the scorching summer, the academic atmosphere of Mengyang Pharmaceutical is very lively, and it has always been firmly patient centered, guided by unmet clinical needs, adhering to integrity and innovation, and continuing to strive! We firmly adhere to the promotion path of professional chemistry, continuously seek the well-being of cancer patients, and improve their quality of life!